First Australian Patient Dosed in Phase 1b Trial of Imugenes Azer cel CAR T Cell Therapy.

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, announced the dosing of the first Australian patient in its Phase 1b trial of azer-cel (azercabtagene zapreleucel), an allogeneic CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Conducted at Sydney's Royal Prince Alfred Hospital, this trial aims to evaluate the safety, tolerability, and efficacy of azer-cel, offering an off-the-shelf alternative to traditional autologous CAR T-cell therapies that require extensive manufacturing using the patient's cells.

Promising results from U.S. cohorts included complete responses in patients who had failed prior treatments, with some achieving durable responses extending over 120 days. This Australian milestone signifies Imugene's commitment to accelerating innovative therapies. CEO Leslie Chong highlighted the therapy's potential to improve outcomes for patients with limited options. Recruitment is set to expand to multiple sites, furthering research into this transformative treatment.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com